Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There are various regimens for thromboprophylaxis after hip replacement. Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some degree. Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use. METHODS: In this double-blind, double-dummy study, we randomly assigned 5407 patients undergoing total hip replacement to receive apixaban at a dose of 2.5 mg orally twice daily or enoxaparin at a dose of 40 mg subcutaneously every 24 hours. Apixaban therapy was initiated 12 to 24 hours after closure of the surgical wound; enoxaparin therapy was initiated 12 hours before surgery. Prophylaxis was continued for 35 days after surgery, followed by bilateral venographic studies. The primary efficacy outcome was the composite of asymptomatic or symptomatic deep-vein thrombosis, nonfatal pulmonary embolism, or death from any cause during the treatment period. Patients were followed for an additional 60 days after the last intended dose of study medication. RESULTS: A total of 1949 patients in the apixaban group (72.0%) and 1917 patients in the enoxaparin group (71.0%) could be evaluated for the primary efficacy analysis. The primary efficacy outcome occurred in 27 patients in the apixaban group (1.4%) and in 74 patients in the enoxaparin group (3.9%) (relative risk with apixaban, 0.36; 95% confidence interval [CI], 0.22 to 0.54; P<0.001 for both noninferiority and superiority; absolute risk reduction, 2.5 percentage points; 95% CI, 1.5 to 3.5). The composite outcome of major and clinically relevant nonmajor bleeding occurred in 129 of 2673 patients assigned to apixaban (4.8%) and 134 of 2659 assigned to enoxaparin (5.0%) (absolute difference in risk, -0.2 percentage points; 95% CI, -1.4 to 1.0). CONCLUSIONS: Among patients undergoing hip replacement, thromboprophylaxis with apixaban, as compared with enoxaparin, was associated with lower rates of venous thromboembolism, without increased bleeding. (Funded by Bristol-Myers Squibb and Pfizer; ClinicalTrials.gov number, NCT00423319.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The WARFASA 309 and ASPIRE 318 trials compared aspirin, 100 mg daily, with placebo for secondary prevention of recurrent VTE for patients with an initial unprovoked event, and the pooled results of the 2 trials showed a decrease in recurrent VTE, as well as major vascular events, without an increased risk for clinically relevant bleeding. 309,315”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [318]
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [318]
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Self-citationPrevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationRivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Lassen, M. R., Ageno, W., Borris, L. C., Lieberman, J. R., Rosencher, N., Bandel, T. J., Misselwitz, F., & Turpie, A. G. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa076016 · Cited by 1,295
Self-citation
Cited by
Kahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Prevention of VTE in Orthopedic Surgery Patients
Falck-Ytter, Y., Francis, C. W., Johanson, N. A., Curley, C., Dahl, O. E., Schulman, S., Ortel, T. L., Pauker, S. G., & Colwell, C. W. (2012) · Chest · doi:10.1378/chest.11-2404 · Cited by 1,930
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
Halvorsen, S., Mehilli, J., Cassese, S., Hall, T. S., Abdelhamid, M., Barbato, E., De Hert, S., de Laval, I., Geisler, T., Hinterbuchner, L., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac270 · Cited by 1,141
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
Alexander, J. H., Lopes, R. D., James, S., Kilaru, R., He, Y., Mohan, P., Bhatt, D. L., Goodman, S., Verheugt, F. W., Flather, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105819 · Cited by 1,005
Management of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology
Kozek-Langenecker, S. A., Afshari, A., Albaladejo, P., Santullano, C. A. A., De Robertis, E., Filipescu, D. C., Fries, D., Görlinger, K., Haas, T., Imberger, G., et al. (2013) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32835f4d5b · Cited by 909
Anderson, D. R., Morgano, G. P., Bennett, C., Dentali, F., Francis, C. W., Garcia, D. A., Kahn, S. R., Rahman, M., Rajasekhar, A., Rogers, F. B., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000975 · Cited by 626
Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients
Goldhaber, S. Z., Leizorovicz, A., Kakkar, A. K., Haas, S. K., Merli, G., Knabb, R. M., & Weitz, J. I. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1110899 · Cited by 547
Weitz, J. I., Eikelboom, J. W., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2294 · Cited by 527
Holster, I. L., Valkhoff, V. E., Kuipers, E. J., & Tjwa, E. T. T. L. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.041 · Cited by 408
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
Byon, W., Garonzik, S., Boyd, R. A., & Frost, C. E. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00775-z · Cited by 348
Frost, C., Wang, J., Nepal, S., Schuster, A., Barrett, Y. C., Mosqueda‐Garcia, R., Reeves, R. A., & LaCreta, F. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04369.x · Cited by 370
Narouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., De Andres, J., Deer, T. R., Rauck, R., & Huntoon, M. A. (2015) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000223 · Cited by 362
Ley, E. J., Brown, C. V. R., Moore, E. E., Sava, J. A., Peck, K., Ciesla, D. J., Sperry, J. L., Rizzo, A. G., Rosen, N. G., Brasel, K. J., et al. (2020) · Journal of Trauma and Acute Care Surgery · doi:10.1097/ta.0000000000002830 · Cited by 294
Wang, X., Tirucherai, G., Marbury, T. C., Wang, J., Chang, M., Zhang, D., Song, Y., Pursley, J., Boyd, R. A., & Frost, C. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.628 · Cited by 286
Frost, C., Nepal, S., Wang, J., Schuster, A., Byon, W., Boyd, R. A., Yu, Z., Shenker, A., Barrett, Y. C., Mosqueda‐Garcia, R., et al. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12106 · Cited by 286
Upreti, V. V., Wang, J., Barrett, Y. C., Byon, W., Boyd, R. A., Pursley, J., LaCreta, F. P., & Frost, C. E. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12114 · Cited by 269
Gomez-Outes, A., Terleira-Fernandez, A. I., Suarez-Gea, M. L., & Vargas-Castrillon, E. (2012) · BMJ · doi:10.1136/bmj.e3675 · Cited by 261
Thromboembolism prophylaxis in orthopaedics: an update
Flevas, D. A., Megaloikonomos, P. D., Dimopoulos, L., Mitsiokapa, E., Koulouvaris, P., & Mavrogenis, A. F. (2018) · EFORT Open Reviews · doi:10.1302/2058-5241.3.170018 · Cited by 229
Sterne, J. A., Bodalia, P. N., Bryden, P. A., Davies, P. A., López-López, J. A., Okoli, G. N., Thom, H. H., Caldwell, D. M., Dias, S., Eaton, D., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21090 · Cited by 198
Pannucci, C. J., Dreszer, G., Wachtman, C. F., Bailey, S. H., Portschy, P. R., Hamill, J. B., Hume, K. M., Hoxworth, R. E., Rubin, J. P., Kalliainen, L. K., et al. (2011) · Plastic and Reconstructive Surgery · doi:10.1097/prs.0b013e31822b6817 · Cited by 200
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
Wong, P. C., Pinto, D. J. P., & Zhang, D. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0551-3 · Cited by 195
“Finally, the APPRAISE-2 finding does not mean that apixaban cannot benefit other patient populations, as recent phase III clinical trials of apixaban have demonstrated promising results in patients with venous thromboembolism (ADVANCE 1, 2, 3) and atrial fibrillation (AVERROES) [18, 21, 22, 46].”
BackgroundResultInfluentialPrevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
Lieberman, J. R., & Hsu, W. K. (2005) · The Journal of Bone & Joint Surgery · doi:10.2106/jbjs.d.03033 · Cited by 182
Henke, P. K., Kahn, S. R., Pannucci, C. J., Secemksy, E. A., Evans, N. S., Khorana, A. A., Creager, M. A., Pradhan, A. D., & On behalf of the American Heart Association Advocacy Coordinating Committee (2020) · Circulation · doi:10.1161/cir.0000000000000769 · Cited by 176
LEVINE, M. N., GU, C., LIEBMAN, H. A., ESCALANTE, C. P., SOLYMOSS, S., DEITCHMAN, D., RAMIREZ, L., & JULIAN, J. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04693.x · Cited by 190
Self-citationOverview of the New Oral Anticoagulants: Opportunities and Challenges
Yeh, C. H., Hogg, K., & Weitz, J. I. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.303397 · Cited by 189
“The efficacy and safety of dabigatran in this setting are comparable with those of enoxaparin, whereas apixaban is more effective than once daily enoxaparin and equally effective as twice daily enoxaparin with a similar risk of major bleeding.(5,6) Therefore, the NOACs offer a convenient alternative to enoxaparin in e…”
BackgroundSteiner, T., Böhm, M., Dichgans, M., Diener, H.-C., Ell, C., Endres, M., Epple, C., Grond, M., Laufs, U., Nickenig, G., et al. (2013) · Clinical Research in Cardiology · doi:10.1007/s00392-013-0560-7 · Cited by 183
“5 mg apixaban twice daily for 35 days was superior to 40 mg enoxaparin in preventing thrombosis in patients undergoing elective hip replacement surgery, with lower bleeding rates [17].”
Narouze, S., Benzon, H. T., Provenzano, D., Buvanendran, A., De Andres, J., Deer, T., Rauck, R., & Huntoon, M. A. (2017) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000700 · Cited by 164
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban
Chang, M., Yu, Z., Shenker, A., Wang, J., Pursley, J., Byon, W., Boyd, R. A., LaCreta, F., & Frost, C. E. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.633 · Cited by 171
Mueck, W., Schwers, S., & Stampfuss, J. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-10 · Cited by 165
Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting
Levy, J. H., Faraoni, D., Spring, J. L., Douketis, J. D., & Samama, C. M. (2013) · Anesthesiology · doi:10.1097/aln.0b013e318289bcba · Cited by 165
Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects
Wang, X., Mondal, S., Wang, J., Tirucherai, G., Zhang, D., Boyd, R. A., & Frost, C. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0055-y · Cited by 156
“stroke and systemic embolism in patients with non-valvular atrial fibrillation [3, 4] and for thromboprophylaxis following elective knee or hip replacement surgery [5, 6].”
BackgroundInfluentialAcute management of bleeding in patients on novel oral anticoagulants
Siegal, D. M., & Crowther, M. A. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs408 · Cited by 166
“C row ther 492 Downloaded from https://academic.oup.com/eurheartj/article-abstract/34/7/489/599266 by guest on 29 July 2018 ADVANCE-2, Lassen et al.88 VTE prevention orthopaedic surgery Decrease in Hb ≥ 20 g/L in 24 h Transfusion ≥ 2 units packed red blood cells Bleeding at a critical site (intracranial, intraspinal,…”
BackgroundInfluentialFrost, C. E., Byon, W., Song, Y., Wang, J., Schuster, A. E., Boyd, R. A., Zhang, D., Yu, Z., Dias, C., Shenker, A., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12541 · Cited by 160
Zhao, L., Wu, M., Xiao, C., Yang, L., Zhou, L., Gao, N., Li, Z., Chen, J., Chen, J., Liu, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1504229112 · Cited by 144
Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve
Wang, T. Y., Svensson, L. G., Wen, J., Vekstein, A. M., Gerdisch, M., Rao, V. U., Moront, M. G., Johnston, D., Lópes, R. D., Chavez, A., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2300067 · Cited by 144
Guntupalli, S. R., Brennecke, A., Behbakht, K., Tayebnejad, A., Breed, C., Babayan, L. M., Cheng, G., Ramzan, A. A., Brubaker, L. W., Corr, B. R., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.7410 · Cited by 150
Miller, C., Dorreen, A. P., Martel, M., Huynh, T. T., & Barkun, A. N. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.031 · Cited by 149
“Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation.”
InfluentialGraff, J., & Harder, S. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0034-0 · Cited by 129
“5 mg twice daily [59, 60].”
Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa
Vakkalagadda, B. J., Frost, C. E., Byon, W., Boyd, R. A., Wang, J. J. J., Zhang, D., Yu, Z., Dias, C. S., Shenker, A., & LaCreta, F. P. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0157-9 · Cited by 133
Frost, C. E., Song, Y. J., Barrett, Y. C., Wang, J. J. J., Pursley, J. M., Boyd, R. A., & LaCreta, F. P. (2014) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s61131 · Cited by 139
Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants
Garcia, D. A., Barrett, Y., Ramacciotti, E., & Weitz, J. I. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12096 · Cited by 125
Forster, R., & Stewart, M. C. W. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004179.pub2 · Cited by 135
Venous Thromboembolism: Classification, Risk Factors, Diagnosis, and Management
Moheimani, F., & Jackson, D. E. (2011) · ISRN Hematology · doi:10.5402/2011/124610 · Cited by 130
“Prescribing apixaban after knee and hip replacement was more effective for prevention of VTE as compared with LMWH without enhancing bleeding risk [48, 49].”
Oral Direct Factor Xa Inhibitors
Yeh, C. H., Fredenburgh, J. C., & Weitz, J. I. (2012) · Circulation Research · doi:10.1161/circresaha.112.276741 · Cited by 131
Zhang, Z.-H., Shen, B., Yang, J. Y., Zhou, Z., Kang, P., & Pei, F. (2015) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-015-0470-0 · Cited by 119
“Results Screening results We included 54 papers [11-64] from 226 identified titles, in which about 1,150,000 patients from more than 30 countries and 28 classes of factors were examined.”
BackgroundPerioperative management of patients on direct oral anticoagulants
Dubois, V., Dincq, A.-S., Douxfils, J., Ickx, B., Samama, C. M., Dogné, J., Gourdin, M. J., Châtelain, B., Mullier, F., & Lessire, S. (2017) · Thrombosis Journal · doi:10.1186/s12959-017-0137-1 · Cited by 122
Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)
Gelosa, P., Castiglioni, L., Tenconi, M., Baldessin, L., Racagni, G., Corsini, A., & Bellosta, S. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.07.016 · Cited by 121
How I treat target-specific oral anticoagulant–associated bleeding
Siegal, D. M., Garcia, D. A., & Crowther, M. A. (2014) · Blood · doi:10.1182/blood-2013-09-529784 · Cited by 121
Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants
Chan, N., Eikelboom, J. W., & Weitz, J. I. (2016) · Circulation Research · doi:10.1161/circresaha.116.306925 · Cited by 125
Jørgensen, C. C., Jacobsen, M. K., Søballé, K., Hansen, T. B., Husted, H., Kjærsgaard‐Andersen, P., Hansen, L. T., Laursen, M. B., & Kehlet, H. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003965 · Cited by 121
Levy, J. H., Spyropoulos, A. C., Samama, C. M., & Douketis, J. D. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.06.014 · Cited by 119
Caldeira, D., Barra, M., Santos, A. T., Abreu, D., Pinto, F. J., Ferreira, J. J., & Costa, J. N. (2014) · Heart · doi:10.1136/heartjnl-2013-305288 · Cited by 112
The New Oral Anticoagulants in Clinical Practice
Gonsalves, W. I., Pruthi, R. K., & Patnaik, M. M. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.03.006 · Cited by 112
Gu, Z., Wei, A., Zhang, C., Wang, X., Zhang, L., Shen, L., Li, Z., Pan, M.-M., Liu, X.-Y., Pu, J., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.056 · Cited by 111
The evolution of anticoagulant therapy.
Franchini, M., Liumbruno, G. M., Bonfanti, C., & Lippi, G. (2016) · PubMed · doi:10.2450/2015.0096-15 · Cited by 127
The Effect of Postoperative Enoxaparin on Risk for Reoperative Hematoma
Pannucci, C. J., Wachtman, C. F., Dreszer, G., Bailey, S. H., Portschy, P. R., Hamill, J. B., Hume, K. M., Hoxworth, R. E., Kalliainen, L. K., Rubin, J. P., et al. (2011) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0b013e318236215c · Cited by 107
Raskob, G. E., Gallus, A. S., Pineo, G. F., Chen, D., Ramirez, L.-M., Wright, R. T., & Lassen, M. R. (2012) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.94b2.27850 · Cited by 112
“Asian 252 (16) 254 (17) 182 (7) 188 (7) 434 (10) 442 (11) 343 (10) 345 (10)”
Self-citationBleeding and antidotes in new oral anticoagulants
Majeed, A., & Schulman, S. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.001 · Cited by 99
Fuji, T., Fujita, S., Kawai, Y., Nakamura, M., Kimura, T., Fukuzawa, M., Abe, K., & Tachibana, S. (2015) · Thrombosis Journal · doi:10.1186/s12959-015-0057-x · Cited by 108
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations
Harder, S., & Graff, J. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1510-z · Cited by 102
Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
Bounameaux, H., & Camm, A. J. (2014) · Drugs · doi:10.1007/s40265-014-0261-1 · Cited by 105
Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban
Frost, C. E., Song, Y. J., Shenker, A., Wang, J. J. J., Barrett, Y. C., Schuster, A. E., Harris, S. I., & LaCreta, F. P. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0228-0 · Cited by 105
“Apixaban is approved for prevention of VTE following elective knee or hip replacement surgery and for stroke prevention in patients with NVAF; these patient populations tend to comprise elderly men and women [22–25].”
BackgroundRecent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa
Bauer, K. A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04321.x · Cited by 104
Hoffman, M., & Dickneite, G. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-05-0431 · Cited by 101
Neumann, I., Rada, G., Claro, J. C., Carrasco-Labra, A., Thorlund, K., Akl, E. A., Bates, S. M., & Guyatt, G. H. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00421 · Cited by 94
van Gorp, R. H., & Schurgers, L. J. (2015) · Nutrients · doi:10.3390/nu7115479 · Cited by 103
He, K., Luettgen, J. M., Zhang, D., He, B., Grace, J. E., Xin, B., Pinto, D. J. P., Wong, P. C., Knabb, R. M., Lam, P. Y. S., et al. (2011) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-011-0037-x · Cited by 101
“Apixaban has demonstrated antithrombotic activity in preclinical animal models and clinical efficacy and safety for the prevention of venous thromboembolism in patients who underwent total knee or hip replacement surgery (Lassen et al. 2010a, b; Wong et al. 2008).”
BackgroundPrevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
Lieberman, J. R., & Pensak, M. J. (2013) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.l.01328 · Cited by 102
Old Versus New Oral Anticoagulants: Focus on Pharmacology
Fareed, J., Thethi, I., & Hoppensteadt, D. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134633 · Cited by 97
Recommendations from the ICM-VTE: Hip & Knee
Delegates, T. I.-V. H. &. K. (2022) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.21.01529 · Cited by 100
When Direct Oral Anticoagulants Should Not Be Standard Treatment
Bejjani, A., Khairani, C. D., Assi, A. A., Piazza, G., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Connors, J. M., Siegal, D. M., Barnes, G. D., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.038 · Cited by 98
New oral anticoagulants and regional anaesthesia
Benzon, H. T., Avram, M. J., Green, D., & Bonow, R. O. (2013) · British Journal of Anaesthesia · doi:10.1093/bja/aet401 · Cited by 93
Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis
Tang, L. V., Wu, Y., Lip, G. Y. H., Yin, P., & Hu, Y. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00228-8 · Cited by 90
Grandhi, R., Newman, W. C., Zhang, X., Harrison, G. L., Moran, C. C., Okonkwo, D. O., & Ducruet, A. F. (2015) · World Neurosurgery · doi:10.1016/j.wneu.2015.08.042 · Cited by 87
Vaglio, S., Prisco, D., Biancofiore, G., Rafanelli, D., Antonioli, P., Lisanti, M., Andreani, L., Basso, L., Velati, C., Grazzini, G., et al. (2016) · PubMed · doi:10.2450/2015.0172-15 · Cited by 98
Perioperative management of patients on new oral anticoagulants
Lai, A., Davidson, N. C., Galloway, S., & Thachil, J. V. (2014) · British journal of surgery · doi:10.1002/bjs.9485 · Cited by 85
Mak, K. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001592 · Cited by 89
The perioperative management of new direct oral anticoagulants: a question without answers
Castillo, J., Andrés, J. A. D., Gomar, C. G., Gómez‐Luque, A., Hidalgo, F., Llau, J. V., Sierra, P., Torres, L. M., & Ferrandis, R. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-11-0868 · Cited by 85
“The first trials of this drug were conducted in thromboprophylaxis after major orthopaedic surgery (ADVANCE-1, ADVANCE-2, ADVANCE-3) (15-17).”
BackgroundPetersen, P. B., Kehlet, H., Jørgensen, C. C., & on behalf of the Lundbeck Foundation Centre for Fast-track Hip and Knee Replacement Collaborative Group (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1675641 · Cited by 85
Lieberman, J. R., & Heckmann, N. D. (2017) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-15-00760 · Cited by 79
Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants
Enriquez, A. A., Lip, G. Y. H., & Baranchuk, A. M. (2015) · EP Europace · doi:10.1093/europace/euv030 · Cited by 81
Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
Cirincione, B. B., Kowalski, K. G., Nielsen, J. C., Roy, A., Thanneer, N., Byon, W., Boyd, R. A., Wang, X., Leil, T. A., LaCreta, F. P., et al. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12347 · Cited by 81
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism
Steffel, J., & Braunwald, E. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr052 · Cited by 78
Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa
Siegal, D. M., Lu, G., Leeds, J. M., Karbarz, M. J., Castillo, J., Mathur, V. S., Hutchaleelaha, A., Sinha, U., Kitt, M. M., McClure, M. W., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007112 · Cited by 75
Venker, B. T., Ganti, B. R., Lin, H., Lee, E. D., Nunley, R. M., & Gage, B. F. (2016) · The Journal of Arthroplasty · doi:10.1016/j.arth.2016.09.033 · Cited by 75
Nieto, J. A., Espada, N. G., Merino, R. G., & Cámara, T. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.02.011 · Cited by 79
Venous Thromboembolic Prophylaxis After Total Hip and Knee Arthroplasty
Lieberman, J. R., & Bell, J. A. (2021) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.20.02250 · Cited by 77
New oral anticoagulants in elderly patients
Barco, S., Cheung, Y. W., Eikelboom, J. W., & Coppens, M. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.011 · Cited by 70
Feng, W., Wu, K., Liu, Z., Kong, G., Deng, Z., Chen, S., Wu, Y., Chen, M., Liu, S., & Wang, H. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.10.009 · Cited by 71
“The other 8 RCTs evaluated only one dose of direct factor Xa inhibitor [34–41].”
BackgroundCaldeira, D., Barra, M., Ferreira, A., Rocha, A., Augusto, A., Pinto, F. J., Costa, J. N., & Ferreira, J. J. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13412 · Cited by 73
Johnston, S. (2016) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2015.12.010 · Cited by 73
Lung cancer associated venous thromboembolic disease: A comprehensive review
Corrales, L., & Blais, N. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.07.004 · Cited by 67
Pegourié, B., Karlin, L., Benboubker, L., Orsini‐Piocelle, F., Tiab, M., Auger‐Quittet, S., Rodon, P., Royer, B., Leleu, X. P., Bareau, B., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25459 · Cited by 67
Becattini, C., Vedovati, M. C., & Agnelli, G. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2011.12.014 · Cited by 69
“THR surgery (Table 2) [17–19].”
Nederpelt, C. J., Naar, L., Krijnen, P., le Cessie, S., Kaafarani, H. M. A., Huisman, M. V., Velmahos, G. C., & Schipper, I. B. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005059 · Cited by 62
New anticoagulants: how to deal with treatment failure and bleeding complications
Kazmi, R. S., & Lwaleed, B. A. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04060.x · Cited by 62
The Prophylaxis of Venous Thromboembolism
Encke, A., Haas, S. K., & Kopp, I. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0532 · Cited by 75
Subramanian, V. B., Katari, N. K., Dongala, T., & Jonnalagadda, S. B. (2019) · Biomedical Chromatography · doi:10.1002/bmc.4719 · Cited by 64
Use of anticoagulants in elderly patients
Bauersachs, R. M. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.09.013 · Cited by 67
“5 mg bid) versus enoxaparin (40 mg od) in patients undergoing THR, and the results demonstrated superior efficacy for apixaban compared with enoxaparin, with similar rates of major and non-major clinically relevant bleeding [68].”
Metadata
- Authors
- Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., & Ramirez, L. M.
- Affiliations
- University of Copenhagen (DK)
- South Australia Pathology (AU)
- University of Oklahoma Health Sciences Center (US)
- University of Calgary (CA)
- Bristol-Myers Squibb (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-23
- Volume
- 363
- Issue
- 26
- Pages
- 2487-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2133686162
- Cited by
- 775
- References
- 35
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 32 · 2023: 18 · 2022: 25 · 2021: 33 · 2020: 34 · 2019: 39 · 2018: 41 · 2017: 39 · 2016: 62 · 2015: 66 · 2014: 67 · 2013: 121 · 2012: 102
- FWCI
- 76.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Murdoch University Research Portal (submittedVersion)
- Flinders Academic Commons (Flinders University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, enoxaparin, thromboprophylaxis, total hip arthroplasty, factor Xa inhibitors, low molecular weight heparin, deep vein thrombosis, pulmonary embolism, bleeding risk, venography, non-inferiority, postoperative thromboprophylaxis, oral anticoagulants, venous thromboembolism
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Hemorrhage, Humans, Injections, Subcutaneous, Male, Middle Aged, Postoperative Complications, Pyrazoles, Pyridones, Confidence Intervals, Treatment Outcome, Enoxaparin, Arthroplasty, Replacement, Hip, Venous Thromboembolism, Young Adult, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.